GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Inventory-to-Revenue

Antares Pharma (Antares Pharma) Inventory-to-Revenue : 0.28 (As of Mar. 2022)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Antares Pharma's Average Total Inventories for the quarter that ended in Mar. 2022 was $11.6 Mil. Antares Pharma's Revenue for the three months ended in Mar. 2022 was $41.6 Mil. Antares Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.28.

Antares Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2022 declined from Dec. 2021 (0.29) to Dec. 2021 (0.28)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Antares Pharma's Days Inventory for the three months ended in Mar. 2022 was 56.24.

Inventory Turnover measures how fast the company turns over its inventory within a year. Antares Pharma's Inventory Turnover for the quarter that ended in Mar. 2022 was 1.62.


Antares Pharma Inventory-to-Revenue Historical Data

The historical data trend for Antares Pharma's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Inventory-to-Revenue Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.16 0.11 0.11 0.08

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.43 0.37 0.29 0.28

Competitive Comparison of Antares Pharma's Inventory-to-Revenue

For the Medical Instruments & Supplies subindustry, Antares Pharma's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antares Pharma's Inventory-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Antares Pharma's Inventory-to-Revenue falls into.



Antares Pharma Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Antares Pharma's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Inventory-to-Revenue (A: Dec. 2021 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2020 ) + Total Inventories (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )
=( (18.216 + 11.544) / 2 ) / 183.982
=14.88 / 183.982
=0.08

Antares Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2022 is calculated as

Inventory-to-Revenue (Q: Mar. 2022 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2021 ) + Total Inventories (Q: Mar. 2022 )) / count ) / Revenue (Q: Mar. 2022 )
=( (11.544 + 11.591) / 2 ) / 41.557
=11.5675 / 41.557
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antares Pharma  (NAS:ATRS) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Antares Pharma's Days Inventory for the three months ended in Mar. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2022 )/Cost of Goods Sold (Q: Mar. 2022 )*Days in Period
=11.5675/18.767*365 / 4
=56.24

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Antares Pharma's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2022 ) / Average Total Inventories (Q: Mar. 2022 )
=18.767 / 11.5675
=1.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antares Pharma Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447